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Adeno-associated viruses (AAV) are a common gene therapy tool used to deliver custom             
transgenes to specific targets. Utilizing AAV, researchers engineer non-pathogenic viral vectors           
to supplement insufficient gene products. Genetic illnesses characterized by a single gene            
producing mutant proteins, like hemophilia, are candidates for gene therapy. One restriction to             
AAV mediated gene therapy is the virus’ limited capsid capacity which can package genomes up               
to approximately 4.7 kilobase-pairs. Any cis-regulatory elements (promoters, enhancers, etc.)          
included in AAV vectors must be short yet efficacious. A small fragment of human chromosome               
19 (Chr19) has shown promoter and transcriptional enhancer activity in previous studies. Our             
study investigated the efficacy of multiple enhancer Chr19 fragments on AAV vector            
transduction for hemophilia treatment. To verify vector construction, performance, and liver           
specificity, we produced viruses containing Chr19 fragments coupled with a firefly luciferase            
reporter gene then infected human embryonic kidney cells (HEK-293) and human liver cells             
(Huh7) cells. Transduction efficiency was significantly higher in cells infected by AAV            
containing multiple Chr19 fragments than cells infected by AAV containing other known            
promoters. To explore the efficacy of Chr19 fragments on AAV vector transduction ​in vivo​, we               
imaged luciferase activity in infected mice. Mice injected with vectors containing multiple Chr19             
fragments showed slightly increased liver transduction compared to mice with one or no Chr19              
fragments. Additional iterations of this study replaced the luciferase reporter gene with human             
blood clotting factor IX (hFIX). ​Our data suggest a liver-specific increase in transgene             





Hemophilia is an X-linked recessive bleeding disorder characterized by the misfolding or            
lack of human blood clotting factors. Hallmark symptoms of hemophilia are caused by mutations              
in the genes encoding human blood clotting factors VIII or IX (hFVIII, hFIX). Frequent              
systematic protein replacement therapy is the current mainstay of treatment for hemophilic            
patients (Meeks & Leissinger, 2019). Hemophilia is a candidate for the development of gene              
therapy treatments which would offer a one-time injection with long-term benefits. 
One common vehicle for gene therapy is the non-pathogenic adeno-associated virus           
(AAV). A unique transgene can be packaged inside the AAV capsid and expressed in specific               
targets depending on the serotype of the virus or the promoter in the transgene (Chen, et al.,                 
2013). Long-term transgene expression can be achieved; thus the AAV vector is an excellent              
option for supplementing gene deficiencies (Rivière, et al., 2006). The paramount limitation of             
AAV is the capsid’s restricted packaging capability. Custom AAV genomes must be            
approximately 4.7 kb or smaller to be packaged, which limits the size of cis-regulatory elements               
(McCarty, et al., 2001).  
Experimental treatments using AAV to deliver a transgene encoding hFVIII or hFIX to             
hemophilic patients have undergone clinical review. Early clinical trials failed to raise patients’             
levels of clotting factors to therapeutic levels indicating little transgene expression (Nienhuis et             
al., 2017). Recent clinical trials have shown a dose-dependent increase in expression with vector              
administration. Patients’ levels of clotting factors were raised to therapeutic levels 3 months             
post-injection. However, higher dose concentrations of virus correlated with higher chances of            
4 
adverse effects (Doshi & Arruda, 2018). An optimal therapeutic vector must adequately raise             
patients’ clotting factor levels without causing an immune response.  
Wildtype AAV maintains latency in cells by integrating into the cellular genome via a              
region of human chromosome 19, known as AAVS1 (Lamartina et al., 2000; Berns & Linden,               
1995). The AAV genome can be rescued from AAVS1 after superinfection of a helper virus               
(Berns & Linden, 1995). Researchers further investigated AAVS1 and found regions of loose             
chromatin (Lamartina et al., 2000). The DNaseI hypersensitivity of these regions suggested they             
exist as heterochromatin similar to cis-regulatory elements (Lamartina et al., 2000). Additional            
investigation of AAVS1 revealed two small fragments of Chr19 (each approximately347 bp)            
which exhibited enhancer and promoter capabilities. Researchers discovered a smaller          
subfragment (120 bp), which was sufficient to confer liver-specific enhancer activity in mice (C.              
Li, et al., 2009). The exact mechanism of enhancer activity is not yet known however, this short                 
sequence would be beneficial in a viral vector targeting the liver. Many tissue-specific promoters              
are too long to fit within the AAV capsid. A vector containing a short yet robust vector may raise                   
patients’ levels of clotting factor to therapeutic levels without warranting a major immune             
response. 
We examined the effects of inserting multiple Chr19 sub-fragments into a vector for             
hemophilia treatment. We attempted to optimize the AAV vector using multiple enhancer            
fragments to increase liver-specific transgene expression. Here, we compared DNA constructs           
containing various combinations of Chr19 sub-fragments to other promoters upstream of the            
firefly luciferase reporter gene. We chose two previously known liver specific promoters and one              
constitutive promoter (Figure 1). Previous data from our lab suggested the alpha-1-antitrypsin            
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(AIAT) promoter was the least efficient and thus we coupled it with the Chr19 fragments. ​In                
vitro transfections and infections showed significantly increased luciferase activity in cells with            
multiple Chr19 fragments. ​In vivo infections of AAV containing multiple Chr19 fragments            
showed only a slight increase in luciferase production. We then replaced the reporter gene with               
the therapeutic hFIX. ​In vitro transfections displayed no notable trends. These data suggested             
including multiple Chr19 fragments would not enhance hFIX levels in a disease model. Further              
refinement will allow us to determine if the enhancer fragments would be beneficial upstream of               





















DNA constructs, generated previously by Dr. Li, were assembled to contain Chr19            
fragments, a promoter sequence, essential ITR sequences, and a firefly luciferase reporter gene             
as denoted in Figure 1. Systems containing backbone DNA sequences were supplemented with 5              
uL of 10X calf intestinal phosphate (BioLabs, Durham, NC). The systems were incubated for              
one hour at 37°C then run through gel electrophoresis. Using digest software ApE (Wayne              
Davis, Utah), the length of each desired DNA fragment was determined.  
Insert and backbone DNA fragments were excised from gel pieces using a gel extraction              
kit (QIAGEN, Germantown, MD). The DNA fragments were ligated to form the transgene using              
a 1:5 backbone to insert molar ratio.  
 
Transformation  
In preparation of transformation, LB Amp plates and S.O.C. media (Invitrogen, Waltham,            
MA) were heated at 37°C while electroporation cuvettes and SURE cells (Agilent, Santa Clara,              
CA) incubated on ice. Thawed SURE cells and 1 uL of ligation product were added to the                 
electroporation cuvette. Immediately following shock administration, 180 uL S.O.C. media was           






Colonies were picked from plates and placed in separate mini-prep culture tubes            
containing LB broth and 1X ampicillin (Invitrogen, Waltham, MA). These tubes were incubated             
and shaken at 37°C for 18 hours. QIAGEN protocols were followed to isolate and purify the                
DNA. The NanoDrop 2000c Spectrophotometer (Thermo Scientific, Waltham, MA​) was used to            
determine the concentration of DNA in each sample. Each sample was separated into two digest               
systems using SmaI (BioLabs, Durham, NC) and Earl (BioLabs, Durham, NC) restriction            
enzymes. The systems containing EarI incubated at 37°C while the systems containing SmaI             




Mini-prep culture from verified samples was added to LB broth with 1X ampicillin             
(Invitrogen, Waltham, MA). Cultures were incubated at 37°C and shaken for 18 hours.             
Following Invitrogen maxi-prep protocol, plasmids were isolated and purified. The NanoDrop           
2000c Spectrophotometer (Thermo Scientific, Waltham, MA​) was used to determine the           
concentration of DNA in each sample. 
 
Viral Production  
Transfection  
HEK 293 cells were cultured in Dulbecco’s modified Eagle’s medium, DMEM,            
(Corning Inc, Corning, NY) with added 10% fetal bovine serum (Seradigm, Suwannee, GA) and              
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1% penicillin-streptomycin solution (Corning Inc, Corning, NY). The cells were grown in an             
incubator with 5% CO​2 at 37°C. Approximately 18 hours before transfection, nearly 100%             
confluent HEK 293 cells were split in a 1:3 ratio.  
Recombinant AAV was produced using the triple transfection method (Grieger ​et al.​,            
2016). Each plate was transfected with the AAV transgene plasmid, the AAV helper virus              
plasmid containing AAV Rep and Cap genes (pXR9), and the adeno helper plasmid (pXX6-80).              
Polyethylenimine supplemented the transfection systems to allow the DNA through the cell            
membrane.  
Plates were incubated for approximately 60 hours at 37°C with 5% CO​2​. Using             
fluorescent microscopy, the number of cells transfected was visualized on the GFP plates. A              
luciferase assay was prepared to numerate transfection in the non-GFP plates. Luciferase            




Using the existing media, the cells were removed from the infected plates and transferred              
to separate ultracentrifuge tubes. The ultracentrifuge tubes were spun for 10 minutes at 4500              
RPM to separate the cells from used media. Used media was aspirated off. The pellet was                
resuspended in new 1X PBS until the system was 11.7 mL. Cesium chloride (Research Products               
International, Mt. Prospect, IL) was added to the system to establish a molar density gradient               
then vortexed for 10 minutes. Each sample was sonicated for 80 seconds to lyse the cells. The                 
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viruses were added to ultracentrifuge tubes and spun for 18 hours at 60,000 RPM. The viruses                
were eluted from the ultracentrifuge tubes into 1.0 mL fractions.  
Running quantitative PCR, the exact position of the virus within the density gradient was              
located. Fractions containing virus were loaded into separate cassettes and spun in 1X PBS              
solution (GenCore Industries, Orlando, FL). The solution was changed approximately every 2            
hours for 14 hours.  
Purified virus was extracted from the cassettes and titered using quantitative PCR. In             
tandem, an alkaline gel was run to verify the viral genome was the correct length. To get a                  
clearer image of the bands on the alkaline gel, a Southern blot was used.  
 
In vitro ​Infection 
HEK 293 and Huh7 cells were cultured in Dulbecco’s modified Eagle’s medium,            
DMEM, (Corning Inc, Corning, NY) with added 10% fetal bovine serum (Seradigm, Suwannee,             
GA), and 1% penicillin-streptomycin solution (Corning Inc, Corning, NY). The cells were grown             
in an incubator with 5% CO​2 at 37°C. Both cell types were infected with a multilicity of                 
infection (MOI) of 4000 to check transduction efficiency of each vector. The cells were              
incubated for 48 hours at 37°C with 5% CO​2​.  
A luciferase assay was prepared to numerate transduction in infected cells. Luciferase            





In vivo ​Infection 
Mice were maintained following NIH guidelines as approved by the UNC Institutional            
Animal Care and Use Committee (IACUC). Each virus was injected into 5 separate mice. The               
amount of each virus needed varied in relation to their titers thus viruses were diluted with 1X                 
PBS to equilibrate titers. Approximately 300uL of diluted virus was injected into each mouse.              
Dr. Li performed a retro-orbital injection to administer the viruses.  
Live mice were imaged 3 days post injection and again 7 days post injection. Mice were                
anaesthetized then injected with luciferin-D via retro-orbital injection. After a 5 minute            
incubation period, mice were imaged for 5 minutes using a charge-coupled device camera             





















































Features unique to the short arm of human chromosome 19 (Chr19) allow for the              
integration of the AAV genome in the presence of AAV’s replication proteins (Li, ​et al., 2009).                
The site at which the AAV genome integrates is known as AAVS1 (Lamartina ​et al.​, 2000;                
Berns & Linden, 1995). One region of AAVS1 showed hypersensitivity to DNaseI treatment             
suggesting it exists as heterochromatin (Lamartina ​et al.​, 2000). Analysis of this short (347-base              
pair long) sequence revealed its ​cis regulatory elements (Li, ​et al., 2009). Multiple cell lines               
demonstrated promoter activity independent of Chr19 fragment orientation (Lamartina ​et al.​,           
2000). Further analysis determined a 120 bp subfragment was sufficient to confer liver-specific             
enhancer activity in mice (Li, ​et al., 2009). In this study we examined the effects of including                 
multiple Chr19 subfragments in a single transgene, and compared the enhancer activity to other              
known promoters.  
 
Multiple Chr19 fragments function as enhancers in vitro 
 We first sought to verify if multiple Chr19 fragments included in a single construct would               
increase enhancer activity. To examine enhancer activity, we developed plasmids containing           
various combinations of Chr19 fragments upstream of the alpha-1-antitrypsin (AIAT) promoter.           
We cloned the firefly luciferase reporter gene into the constructs to easily visualize transgene              
product synthesis. Constructs were compared to other known promoters by quantification of            
luciferase activity. Transfected HEK 293 and Huh7 cells demonstrated significantly more           
transgene expression independent of Chr19 orientation compared to the AIAT promoter (p <             
0.0001; Figure 2a). Plasmids containing two Chr19 fragments, independent of orientation,           
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exhibited similar luciferase activity as the known hybrid liver promoter (HLP) in Huh7 cells              
(Figure 2a). Plasmids containing single Chr19 fragments significantly underperformed plasmids          
containing two Chr19 fragments (p < 0.05; Figure 2a). The known constitutive promoter, chicken              
ß-actin (CBA), served as a positive control producing significantly more luciferase than any             
other experimental plasmid. In sum, plasmids containing multiple Chr19 fragments exhibited           
increased transgene transduction.  
 We next developed the plasmids into viral vectors to verify their enhancer function when              
delivered via AAV. Huh7 cells infected with viruses containing Chr19 fragments showed            
increased transgene expression in a stepwise manner (Figure 2b). The virus containing two             
Chr19 fragments significantly outperformed viruses containing one or no fragments (p < 0.001, p              
< 0.0001; Figure 2b). Notably, cells infected by virus containing multiple Chr19 fragments             
produced more luciferase in both cell lines than all other experimental promoters except the              
constitutive CBA promoter (Figure 2b). 
Across both experiments, multiple Chr19 fragments correlated to an increase in transgene            
expression. The constitutive CBA promoter significantly outperformed all other experimental          
constructs and viruses.  
 
Multiple Chr19 fragments enhancer function & liver specificity in vivo 
 We next moved to verify multiple Chr19 fragments would increase AAV transduction,            
specifically in the liver, ​in vivo​. AAV9 itself does not demonstrate tissue-specific infection.             
Imaging data showed all viruses successfully induced luciferase production in mice days            
following injection (Figure 3a). Mice injected with Chr19 variant viruses, displayed luciferase            
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activity in the liver’s approximate location (Figure 3a). The virus containing the CBA promoter              
showed strong luciferase expression without tissue specificity (Figure 3a). 
 Imaging data was quantified, numerating luciferase production. After 3 days, viruses           
containing two Chr19 fragments displayed significantly more luciferase activity when compared           
to viruses with only one Chr19 fragment or the AIAT promoter alone (p < 0.05; Figure 3b). The                  
known promoter, HLP, outperformed all Chr19 variants in luciferase production (Figure 3b).            
After one week, viruses containing one Chr19 fragment displayed an increase in luciferase             
production compared to viruses with two Chr19 fragments or the AIAT promoter alone (Figure              
3c). Again, viruses containing HLP outperformed all Chr19 variants in luciferase production            
(Figure 3c). Luciferase production increased across all viruses after one week (Figure 3c). 
 In sum, the Chr19 variants displayed greater transgene expression compared to the AIAT             
promoter. The Chr19 variants did not, however, outperform the other known promoters ​in vivo. 
 
Multiple Chr19 fragments’ enhancer function in hemophilia model 
 To mimic hemophilia treatment, the firefly luciferase gene was replaced with human            
blood clotting factor IX (hFIX). New constructs were compared to other known promoters by              
quantification of hFIX. Transfected HEK 293 and Huh7 cells showed decreased transgene            
expression in Chr19 variants compared to the AIAT promoter (Figure 4). There was no              
significant difference between constructs containing the Chr19 variants (Figure 4). Plasmids           
containing variant Chr19 stuffer sequences (mvm) showed a significant decrease in hFIX            
expression compared to non-stuffer plasmids (p< 0.001; Figure 4). Constructs containing AIAT            
promoter variants (with or without stuffer sequence) displayed no significant difference in hFIX             
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We sought to identify enhancer sequences that promote expression of virally-delivered           
genes in the liver. Multiple Chr19 fragments showed increased liver-specific transgene           
expression ​in vitro ​compared to other known promoters. The same constructs in AAV showed              
only a slight increase in liver-specific protein production ​in vivo. We encountered unexpected             
results after replacing the reporter gene with the therapeutic hFIX gene. All constructs containing              
Chr19 fragment combinations showed decreased expression of hFIX. Moreover, constructs          
containing the stuffer sequence (mvm) from previous trials displayed the least hFIX production.  
 The enhancer function of multiple Chr19 fragments was less than expected. We decided             
an effective enhancer should raise the transgene expression at least 5-fold to be included in a                
therapeutic vector. Initial ​in vitro ​infections of vectors with two Chr19 fragments upstream of the               
alpha-1-antitrypsin (AIAT) promoter displayed luciferase production comparable to the known          
hybrid liver promoter (HLP). These data support the use of the enhancer fragments for vector               
optimization since the small AIAT promoter drives poor gene expression in comparison to the              
medium length HLP. We were unable to corroborate these findings during ​in vivo ​infections.              
Although multiple Chr19 fragments increased transgene synthesis ​in vivo​, luciferase expression           
was not comparable to that elicited by any known promoters. The discrepancies between our              
findings with cultured cells and mice are likely due to differing profiles of transcription factors               
and cellular machinery (C. Li, ​et al., 2009). The Chr19 fragments did not confer sufficient               
transgene expression levels to merit driving expression in a therapeutic vector. 
Liver-specificity was an important feature of the Chr19 fragments because ideal           
hemophilia treatments are designed to target the liver. Using human liver (Huh7) cells, we              
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demonstrated increased transgene expression in all cases compared to human embryonic kidney            
(HEK 293) cells. We chose to package constructs in AAV serotype 9 because it is known to                 
widely disseminate transduction (Gao et al., 2004). Alone, AAV9 infects a diverse array of cell               
types and tissues, demonstrated by the non-specific production of luciferase in CBA mice. In              
contrast, the Chr19 combination viruses produced luciferase localized approximately to the liver.            
We did not extract organs to determine their genome copy number and specific luciferase              
concentrations. The genome copy number would reveal which organs were preferentially           
infected. We cannot conclude that the enhancer fragments localize expression to the liver, rather              
that the approximate location of the liver was synthesizing high levels of luciferase. Data from               
organ-specific luciferase assays would add certainty to the claim that the Chr19 fragments confer              
liver-specificity. 
We found that multiple Chr19 fragments correlate to greater luciferase production but            
these findings did not translate to our hFIX trials. During early trials confirming the enhancer               
fragments function with the reporter gene, we included a “stuffer sequence” in the vectors.              
Initially, the constructs containing multiple Chr19 fragments upstream of the AIAT promoter and             
luciferase gene were packaged twice in the AAV capsid. Oftentimes transgenes are packaged             
twice in viruses when the genome is significantly smaller than 4.7 kb. The essential inverted               
terminal repeat (ITR) sequences in the transgenes bind together, rendering the vector useless. To              
compensate for this problem, we included a short noncoding DNA sequence to increase the              
genomes’ length. When we moved to the hFIX trials, the stuffer sequence was included in some                
vectors and proved detrimental. Therefore, we conclude that the downstream sequences of the             
transgene may affect the enhancer function of Chr19 fragments.  
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Further examination of the enhancer mechanism of Chr19 fragments is necessary. The            
specific intranuclear functions of the fragments are unknown. The favorable enhancer function of             
the fragments may increase upstream of another promoter. Though HLP is slightly longer than              
the AIAT promoter, it is still a candidate to include in a therapeutic vector. Chr19 fragments may                 
favorably interact with HLP or its associated transcriptional factors and increase gene            
expression. It would be beneficial to build a profile of transcription factors present in Huh7 cells                
to determine what causes the discrepancies between cultured liver cells and ​in vivo cells. The               
gene downstream of the enhancer fragments also seems to be important. Perhaps, the Chr19              
fragments would drive greater expression of some other therapeutic protein like hFVIII.  
The addition of multiple Chr19 fragments does not optimize therapeutic vectors for            
hemophilia. However, we confirmed that the stepwise addition of Chr19 fragments enhances            
liver-specific protein synthesis ​in vitro​. Moving forward, other liver or bleeding disorders could             
benefit from including multiple Chr19 fragments for therapeutic vector optimization. There is            
still need for short, yet efficacious cis-regulatory elements in AAV vectors that raise expression              
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